

## Original Article

## Allogeneic Red Blood Cell Transfusion Following the Total Hip Arthroplasty Triggers the Immunomodulatory Responses

Mahdi Ghorbani Ph.D. Candidate<sup>1</sup>, Fatemeh Yari Ph.D.<sup>1\*</sup>, Mahtab Maghsudlu M.D., MPH<sup>1</sup>, Alireza Manafi Rasi M.D.<sup>2</sup>, Nasser Amirizadeh Ph.D.<sup>1</sup>

<sup>1</sup>Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.

<sup>2</sup>Department of Surgery, Faculty of Medicine Shahid Beheshti University of Medical Sciences, Tehran, Iran.

### ABSTRACT

#### Article history

Received 21 Apr 2017

Accepted 30 Jul 2017

Available online 30 Aug 2017

#### Key words

Blood transfusion

Immunomodulation

Total hip arthroplasty

**Background and Aims:** Total hip arthroplasty (THA) is a common orthopedic surgery. The main focus in the research of THA is immune responses in these patients following the blood transfusion. Therefore, in this study, we evaluated the immune modulation indexes such as T cell amplification, T cell surface markers and also production of cytokines in the patients undergoing THA surgery following blood transfusion.

**Materials and Methods:** A total of 30 patients referred to Imam Hussein Hospital for THA surgery were included in the study between May 2015 to May 2016. Transfusions of 500 ml allogeneic red blood were done during and immediately after recovery of THA operation. Along with pre- and post-operation, immune modulatory effects of transfusion, including proliferation of T lymphocyte, secretion of T cell cytokines such as interferon gamma (IFN- $\gamma$ ), Interleukin(IL)-4 and expression of T lymphocyte surface markers such as human leukocyte antigen D related (HLA-DR) and CD25 were evaluated.

**Results:** Blood transfusion induced the expression of CD25 and HLA-DR markers in the THA patients. Blood transfusion also increased the secretion of IL-4 in post-operative stages in the THA patients. Results showed the increased IL-4 levels after blood transfusion. Whereas the levels of secretion in INF-  $\gamma$  were decreased after blood transfusion.

**Conclusions:** Allogeneic blood transfusion in the patients with the THA induced a cascade of immune and inflammatory responses, including increasing in T cell amplification and change in the secretion of interleukins that causes a modulation of immune responses. Further investigations should be performed to verify this hypothesis.

## **Introduction**

Total hip arthroplasty (THA) is a prevalence and successful orthopedic surgical procedure performed in the recent decade. Regarding to the increasing rate of THA frequency, it can be predicted that its occurrence will reach to 137% in the 2030 [1, 2]. Blood loss is commonly occurred along with THA operation and therefore in this surgery the risk of transfusion of allogeneic red blood cell (RBC) is higher than 30 percentages [3, 4]. However, transfusion of allogeneic blood is commonly associated with several risks and complications such as allergic reactions, transmission of infectious agents and immune modulatory effects [5, 6]. These responses are related to the foreign antigens in both the soluble and the cell-associated forms. The presence of these elements in the circulation can cause alloimmunization and down regulation of the immune responses. The regulation of immune responses has generally been referred to as transfusion-associated immunomodulation (TRIM). It has been reported that TRIM has been associated with some immunological signs such as decreased helper to suppressor T cell ratio; decreased NK cell function; defective antigen presentation; and reduction in cell mediated immunity [7, 8]. Previously, it has been revealed that allogeneic transfusion is associated with increasing in lymphomas rate diagnosed during 5 to 10 years of post-transfusion [9]. Since lymphomas are the most important elements of acquired defects of the immune system, these results confirm the hypothesis that transfusion causes a mild to

moderate deficiency of immune functions [10]. Recent studies suggest that altered cytokine regulation may contribute to transfusion-associated immunomodulation [10, 11]. Allogeneic transfusion seems to drive the immune system toward a T helper (Th)2 response and away from a Th1 response [12, 13], providing a hypothetical mechanism for transfusion-induced immunomodulatory effects. The TRIM has been suggested as possible mechanisms for clinical effects such as allograft rejection [14], increased rates of cancer recurrence [15, 16], increased prevalence of bacterial infections, reduced rates of spontaneous abortion [17], improvement in some diseases such as Crohn's disease and rheumatoid arthritis [14], rapid progression of chronic viral infections, and transfusion-related multiple organ dysfunction syndrome [18]. There is limited information about the immunomodulation responses of allogeneic RBC transfusion following the THA surgery [19]. Therefore, in this study, we surveyed the impacts of allogeneic RBC transfusion following the THA surgery on the indicators of immunomodulation, including T cells proliferation, some biomarkers expression and also the profile of cytokine production.

## **Materials and Methods**

### **Patients and settings**

Patients with osteoarthritis undergoing THA in Imam Hussein Hospital (IHH) were included in the study between May 2015 and May 2016. It is of note that the patients with autologous

blood transfusion, age less than 18 years, history of liver disease, coagulation disorder, and autoimmune disease or those were under treatments with immune suppressive drugs were excluded from the study. All patients were given informed consent before inclusion in the research. This study was conducted in accordance with the "Declaration of Helsinki for Human Research" and the protocol was accepted by the University Ethics Committee at High Institute for Research and Education for Transfusion Medicine (IR.TMI.REC.1393.7).

#### **The isolation of peripheral blood mononuclear cells (PBMCs)**

Transfusion of 500 ml red blood cell (RBC) was done during and immediately after recovery of THA operation. Ten milliliter of whole blood samples were collected in Ethylenediaminetetra acetic acid plastic tubes, one hour before the operation and three days after the operation in the groups of RBC transfusion and none transfusions. Blood was diluted with an equal amount of 1X phosphate buffered saline (PBS). Subsequently, PBMCs were isolated by ficoll (Ficoll-Hypaque 1.077, cedar lane, Canada) density gradient centrifugation.

#### **T cell isolation**

For magnetic labeling, the suspensions of  $10^7$  PBMCs were centrifuged at  $300\times g$  for 10 minutes. Pellets were re-suspended in 40  $\mu\text{L}$  of buffer (0.05% sodium azide). In the next step, 10  $\mu\text{L}$  of Pan Tcell biotin-antibody cocktail was added to the suspension and after incubation in the refrigerator ( $2-8^\circ\text{C}$ ) for 5 minutes, 30  $\mu\text{L}$  of buffer was again added. 20  $\mu\text{L}$  of pan T cell micro bead cocktail were added and incubated

for 10 minutes in the refrigerator ( $2-8^\circ\text{C}$ ), and proceeded to magnetic separation with magnetic particle concentrator (Invitrogen, USA) following the manufacturer's instructions (Miltenyi Biotec, Order no. 130-096-535). Flow cytometry (Partec cyflow) with FITC-conjugated anti CD3 (BD, USA), FITC-conjugated mouse anti-human CD25 (BD, USA) and PE-conjugated mouse anti human leukocyte antigen D related (HLA-DR) (BD, USA) were used to survey the expression of CD25 and HLA-DR surface markers on T cells of all the studied groups.

#### **T cell proliferation assay**

Firstly,  $2\times 10^5$  of isolated T cells were cultured in the Roswell Park Memorial Institute (RPMI) medium included 10% fetal bovine serum (FBS) for 72 hours, and the proliferation of the cells were evaluated by WST-1 Cell Proliferation Assay Kit (Cayman, USA) and K562 (Pasteur Institute, Iran) as the control cells. This assay was based on the enzymatic cleavage of the tetrazolium salt WST-1 to formazan by cellular mitochondrial dehydrogenases present in the viable cells. Briefly,  $10^7$  cells of the culture media were added into the wells of a culture plate and 10  $\mu\text{L}$  of the reconstituted WST-1 mixture was added to each well. After mixing, cells were incubated at  $37^\circ\text{C}$  in a  $\text{CO}_2$  incubator for four hours. Finally, the absorbance of the wells was measured using a micro plate reader at the wavelength of 450 nm.

#### **Cytokine production**

For the measurement of cytokines in the supernatants of the cultured T cells, the quantity of Interleukin (IL)-4 and interferon gamma

(IFN- $\gamma$ ) was measured by the enzyme-linked immunosorbent assay (ELISA) Kit (Invitrogen, USA) using Anthos 2020 ELISA reader (Austria) in accordance with the manufacturer's instructions.

**Statistical analysis**

Statistical analysis was performed using the statistical package SPSS (SPSS, Chicago, IL, USA). The mean values ( $\pm$ SD) for IFN- $\gamma$  and IL-4 Student's t-tests were calculated. P-values of  $\leq 0.05$  were used to show the significant differences.

**Results**

Out of 30 patients included in this study, one

group comprised of 15 patients who were transfused with 2 to 4 units of RBC. Expression of CD25 and HLA-DR in the pre and post operation groups shows that this biomarker was significantly increased after THA surgery (Table 1. and Fig. 1). As it was shown, the THA surgery increased the expression of mentioned biomarkers near to two folds in comparison with the pre-operative groups. Results also indicated that transfusion of allogeneic red blood cells in the post operation status increased the expression of CD25 and HLA-DR, although these changes were not significant (Table 2).

**Table 1.** Comparison of CD25 and HLA-DR expression in pre and post operation status


Biomarker	Position	Number of patients	Mean $\pm$ SD (%)	P-Value
CD25	Pre operation	10	6.76 $\pm$ 1.4	0.001
	Post operation	10	15.98 $\pm$ 4.92	
HLA-DR	Pre operation	10	9.68 $\pm$ 4.10	0.001
	Post operation	10	17.36 $\pm$ 6.01	

**Table 2.** Effects of transfusion on CD25 and HLA-DR expression in the post operation patients

Biomarker	Position	Number of patients	Mean (rank)	P-Value
CD25	Transfused	7	6.00	0.51
	Non-Transfused	3	4.33	
HLA-DR	Transfused	7	6.14	0.38
	Non-Transfused	3	4.00	

Comparison of T cells amplification in transfused and non-transfused patients showed that transfusion of allogeneic red blood cells decreases the amplification rate of the T cells in

both the pre and post operation of THA (Table 3). As shown in table 3, these differences between the transfused and non-transfused groups were significant ( $p < 0.01$ ).



**Fig. 1.** Flow cytometry plot. The expression analysis of CD3, CD25 and HLA-DR on the surface of T cells of THA patients after operation and blood transfusion. **A:** Gating of the isolated cell population; **B:** Isotype control; **C:** The level of CD25 Expression on the isolated cells; **D:** The level of HLA-DR Expression on the isolated cells; **E:** The level of CD3 Expression on the isolated cells.

**Table 3.** Comparison of the T cells amplification in transfused and non-transfused patients

Patients	Number of patients	Transfusion status	Mean± SD	P-Value
Pre-operation	15	Transfused	0.22±0.040	0.001
		Non-Transfused	0.265±0.030	
Post-operation	15	Transfused	0.467±0.073	0.001
		Non-Transfused	0.334±0.032	

Secretion of two cytokines (IL-4 and INF- $\gamma$ ) was also surveyed in the pre and post operation groups that were transfused with allogeneic red blood cells. Results showed that transfusion decreased the IL-4 concentration in comparison to non-transfused patients in the pre-operation groups. As shown in table 4, the mean concentrations of IL-4 in the non-transfused and transfused groups were  $5.02\pm 0.60$  and  $5.62\pm 0.63$  pg/ml, respectively. After THA surgery, these patterns were

different. Results showed that following the THA transfusion triggered the secretion of IL-4 in comparison to the non-transfused groups. These changes were significant ( $p=0.001$ ) (Table 4). Regarding the INF- $\gamma$ , transfusion decreased the concentration of INF- $\gamma$ . As shown in table 4, the concentrations of INF- $\gamma$  in the transfused and non-transfused group were  $0.15\pm 0.03$  and  $0.168\pm 0.036$ , respectively (Table 4). However, the differences were not significant ( $p=0.32$ ).

**Table 4.** Effects of transfusion in the concentration of IL-4 and INF- $\gamma$  in pre and post operation patients.

Patients		IL-4			INF- $\gamma$		
		Transfusion status			Transfusion status		
		Transfused	Non-transfused	P-value	Transfused	Non-transfused	P-value
<b>Pre-operation</b>	15	$5.02\pm 0.60$	$5.62\pm 0.63$	0.001	$0.17\pm 0.05$	$0.2\pm 0.60$	0.1
<b>Post-operation</b>	15	$7.63\pm 0.59$	$6.38\pm 0.53$	0.001	$0.15\pm 0.03$	$0.168\pm 0.036$	0.32

Data are presented as Mean $\pm$ SD; IL-4=Interleukin-4; INF- $\gamma$ = Interferon gamma

## Discussion

In this study, we observed that the lymphocyte proliferation was significantly higher in the transfused patients following THA surgery compared to one day before surgery or than in non-transfused groups. This is in contrast with the results of the previous report of Yu et al. [20]. Unlike the results of our study, he and coworkers showed that the lymphocyte proliferation rate that was promoted by RBC was significantly reduced after surgery.

Expression of major histocompatibility complex II is an essential element in the immune response and it is a prerequisite for the effective antigen presentation [21]. Reduced levels of HLA-DR expression following the surgery have

been found [21]. Also, Handy et al. [22] declared that surgery operations cause a reduction in the expression of HLA-DR biomarker. Unlike previous reports, the results of our study showed that the expression of CD25 and HLA-DR on the lymphocyte membrane was increased after the surgery compared with before the surgery and transfused than non-transfused group. This is in contrast with the previous reports [20]. Yu et al. [20] declared that the expression of RBC membrane markers; CD35, CD58 and CD59 were significantly decreased in the postoperative phase compared to pre-operative levels. In line with us, Baumgartner [23], and

also Cata [24], showed that the transfusions of RBC increased the expression of CD25. Moreover, Sun et al. reported that blood transfusion in cancerous patients causes increased levels of CD25 expression, which was in agreement with our results. These increased expressions improved the antigenic presentation and diagnosis by T cells [25]. On the other hand, the overexpression of CD25 inhibited T cells amplification and activation of IL-2 signaling pathways and consequent modulation of immune responses [26]. T cells comprise CD3/CD4 helper/inducer and CD3/CD8 cytotoxic/suppressor lymphocytes with two distinct functions: Th1 lymphocytes produce IFN- $\gamma$  and IL-2, whereas Th2 are producers of IL-4 and IL-10 [12, 27]. The balances between the two types of T cells are crucial for the immune regulation. Therefore, disturbance in the levels of each of the T cell types causes on the effects of different diseases. It has been proposed that cytokine regulation is one of the mechanisms in the transfusion-related immunomodulation [28-30]. In the present study, we have surveyed the influence of allogeneic red cell transfusion following the THA surgery on the production of IFN- $\gamma$  and IL-4 as a functional index of immunologic responses. IL-4 induces the differentiation of B lymphocytes, cytotoxic activity of T lymphocytes and acts as inhibitory elements for the production of pro-inflammatory cytokines [31]. Increased IL-4 production took place in the patients who received transfusion following THA surgery. In line with the results of this study, Pandey et al. [32] reported that in the patients who received allogeneic transfusion, a

remarkable increase in both IL-4 and IL-10 was seen as compared to those patients who received either no transfusion or autologous transfusion. Moreover, increasing the IL-4 transcripts in the graft and spleen using a murine heart allograft model has been reported [33, 34]. No significant change in the levels of Th1 pathway cytokine (IFN- $\gamma$ ) was seen in the patients who received transfusion following THA surgery. In contrast, Bordin et al., [35] reported that the transfused patients with allogeneic RBCs following the hip replacement surgery had decreased levels of IFN- $\gamma$  and tumor necrosis factor (TNF)- $\alpha$ . IFN- $\gamma$  induces the expression of MHC class-II molecules, and consequently stimulating a specific immune response. Furthermore, it induces the activation of monocytes and macrophages and their production of inflammatory cytokines such as TNF- $\alpha$  and IL-1 [36, 37]. In consistence with the overall results of this study, it has been proposed that the anti-inflammatory cytokines such as IL-4, IL-10 and IL-13 serve to down-regulate synthesis of pro-inflammatory cytokines IL-1, IL-6, TNF- $\alpha$  and IFN- $\gamma$  [20, 30, 38]. Interestingly IL-4 induce bone formation and other anti-inflammatory cytokines do not induce bone [39]. Higher levels (6-7 pg/ml) of this cytokine found in our study can be a clue to better improvements in the patients with THA surgeries. Our study had some limitations such as low size of samples. Further research is needed for evaluation of other immunological indexes such as other cytokines in THA and also in transfused patients in order to get complete insights about the immunological modulation in THA surgery.

## Conclusion

Patient blood management and utilization of transfusion therapy based on local guidelines in THA surgery can be the effective ways to reduce the patient's complications related to transfusion-associated immunomodulation. Optimizing the patients' conditions before the surgery among the elective patients can be an effective way in improving outcomes of

the treatment in the patients who undergo orthopedic surgery.

## Conflict of Interest

There are no conflicts of interest or financial involvement with this manuscript as confirmed by all authors.

## Acknowledgment

This research project was supported by Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran. This support is highly appreciated.

## References

- [1]. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. *J Bone Joint Surg Am.* 2007; 89(4): 780-85.
- [2]. Harris RN, Moskal JT, Capps SG. Does tranexamic acid reduce blood transfusion cost for primary total hip arthroplasty? A case control study. *J Arthroplasty* 2015; 30(2): 192-95.
- [3]. Hasley PB, Lave JR, Hanusa BH, Arena VC, Ramsey G, Kapoor WN, et al. Variation in the use of red blood cell transfusions. A study of four common medical and surgical conditions. *Med care.* 1995; 33(11): 1145-160.
- [4]. Use of blood products for elective surgery in 43 European hospitals. The sanguis study group. *Transfus med.* 1994; 4(4): 251-68.
- [5]. Keating EM, Ritter MA. Transfusion options in total joint arthroplasty. *J arthroplasty* 2002; 17(4, Suppl 1): 125-28.
- [6]. Holt JB, Miller BJ, Callaghan JJ, Clark CR, Willenborg MD, Noiseux NO. Minimizing blood transfusion in total hip and knee arthroplasty through a multimodal approach. *J Arthroplasty* 2016; 31(2): 378-82.
- [7]. Bordin JO, Heddle NM, Blajchman MA. Biologic effects of leukocytes present in transfused cellular blood products. *Blood* 1994; 84(6): 1703-721.
- [8]. Blajchman MA. Immunomodulatory effects of allogeneic blood transfusions: clinical manifestations and mechanisms. *Vox sanguinis* 1998; 74 (Suppl 2): 315-19.
- [9]. Blomberg J, Moller T, Olsson H, Anderson H, Jonsson M: Cancer morbidity in blood recipients- results of a cohort study. *Euro J cancer* 1993; 29a(15): 2101-105.
- [10]. Blumberg N, Kirkley SA, Heal JM. A cost analysis of autologous and allogeneic transfusions in hip-replacement surgery. *Am J Surg* 1996; 171(3): 324-30.
- [11]. Hart A, Khalil JA, Carli A, Huk O, Zukor D, Antoniou J. Blood Transfusion in Primary Total Hip and Knee Arthroplasty. Incidence, Risk Factors, and Thirty-Day Complication Rates. *J Bone Joint Surg Am.* 2014; 96(23): 1945-951.
- [12]. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. *Immunol today* 1996, 17(3): 138-46.
- [13]. Kirkley SA, Cowles J, Pellegrini VD, Harris CM, Boyd AD, Blumberg N. Cytokine secretion after allogeneic or autologous blood transfusion. *Lancet* 1995; 345(8948): 527.
- [14]. Post S, Kunhardt M, Sido B, Schurmann G, Herfarth C. Effect of blood transfusions on rate of recurrence of Crohn disease. *Chirurg* 1992, 63(1): 35-8.
- [15]. Blumberg N, Heal JM. Effects of transfusion on immune function. Cancer recurrence and infection. *Arch Pathol Lab Med.* 1994; 118(4): 371-79.
- [16]. Heiss MM, Mempel W, Delanoff C, Jauch KW, Gabka C, Mempel M, et al. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. *J Clin Oncol.* 1994; 12(9): 1859-867.
- [17]. Hill JA, Polgar K, Anderson DJ. T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion. *Jama* 1995; 273(24): 1933-936.
- [18]. Moore FA, Moore EE, Sauaia A. Blood transfusion. An independent risk factor for postinjury multiple organ failure. *Arch surg.* 1997; 132(6): 620-24.
- [19]. van der Heide HJL, van der Kraan PM, Rijnberg WJ, Buma P, Schreurs BW. Elevated levels of numerous cytokines in drainage fluid after primary total hip arthroplasty. *Int orthopaedics* 2010; 34(8): 1099-102.



- [20]. Yu D, Yin Z, Fu C, Yu R: Impact on red blood cell immunity patterns in postoperative phase following total hip arthroplasty. *Cent Eur J immunol.* 2014; 39(3): 377-83.
- [21]. Wakefield CH, Carey PD, Foulds S, Monson JRT, Guillou PJ. Changes in major histocompatibility complex class II expression in monocytes and T cells of patients developing infection after surgery. *Br J Surg.* 1993; 80(2): 205-209.
- [22]. Handy JM, Scott AJ, Cross AM, Sinha P, O'Dea KP, Takata M. HLA-DR expression and differential trafficking of monocyte subsets following low to intermediate risk surgery. *Br J Anaesthesia* 2010; 65(1): 27-35.
- [23]. Baumgartner JM, Silliman CC, Moore EE, Banerjee A, McCarter MD. Stored red blood cell transfusion induces regulatory T cells. *J Am Coll Surg.* 2009; 208(1): 110-19.
- [24]. Cata JP, Wang H, Gottumukkala V, Reuben J, Sessler DI. Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions. *Br J Anaesthesia* 2013; 110(5): 690-701.
- [25]. Sun CF, Hsieh YY, Ngan KW, Wang WT. Search for immunomodulatory effects of blood transfusion in gastric cancer patients: flow cytometry of Th1/Th2 cells in peripheral blood. *Ann Clin Lab Sci.* 2001; 31(2): 171-78.
- [26]. Driesen J, Popov A, Schultze JL. CD25 as an immune regulatory molecule expressed on myeloid dendritic cells. *Immunobiol.* 2008; 213(9-10): 849-58.
- [27]. Sad S, Marcotte R, Mosmann TR. Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. *Immunity* 1995; 2(3): 271-79.
- [28]. Baker EA, El-Gaddal S, Williams L, Leaper DJ. Profiles of inflammatory cytokines following colorectal surgery: relationship with wound healing and outcome. *Wound Repair Regen.* 2006; 14(5): 566-572.
- [29]. Neal BC, Rodgers A, Clark T, Gray H, Reid IR, Dunn L, et al. A systematic survey of 13 randomized trials of non-steroidal anti-inflammatory drugs for the prevention of heterotopic bone formation after major hip surgery. *Acta Orthop Scand.* 2000; 71(2): 122-28.
- [30]. Frank SM, Kluger MJ, Kunkel SL. Elevated thermostatic setpoint in postoperative patients. *Anesthesiol.* 2000; 93(6): 1426-431.
- [31]. Vukmanovic-Stejic M, Thomas MJ, Noble A, Kemeny DM. Specificity, restriction and effector mechanisms of immunoregulatory CD8 T cells. *Immunol.* 2001; 102(2): 115-22.
- [32]. Pandey P, Chaudhary R, Aggarwal A, Kumar R, Khetan D, Verma A. Transfusion-associated immunomodulation: Quantitative changes in cytokines as a measure of immune responsiveness after one time blood transfusion in neurosurgery patients. *Asian J Transfu Sci.* 2010; 4(2):78-85.
- [33]. Takeuchi T, Lowry RP, Konieczny B. Heart allografts in murine systems. The differential activation of Th2-like effector cells in peripheral tolerance. *Transplant* 1992; 53(6): 1281-294.
- [34]. Lee JH, Han SB. Patient Blood Management in Hip Replacement Arthroplasty. *Hip Pelvis* 2015; 27(4): 201-208.
- [35]. Bordin JO, Chiba AK, Carvalho KI, Takata ET, Falcao RP, Garcia AB, et al. The effect of unmodified or prestorage white cell-reduced allogeneic red cell transfusions on the immune responsiveness in orthopedic surgery patients. *Transfus.* 1999; 39(7): 718-23.
- [36]. Letourneau S, Krieg C, Pantaleo G, Boyman O. IL-2 and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. *J Allergy Clin Immunol.* 2009; 123(4): 758-62.
- [37]. Carling MS, Jeppsson A, Eriksson BI, Brisby H. Transfusions and blood loss in total hip and knee arthroplasty: a prospective observational study. *J Orthop Surg Res.* 2015; 10(1):48-58.
- [38]. Giannoudis PV. Current concepts of the inflammatory response after major trauma: an update. *Injury* 2003; 34(6): 397-404.
- [39]. Lind M, Deleuran B, Yssel H, Fink-Eriksen E, Thestrup-Pedersen K. IL-4 and IL-13, but not IL-10, are chemotactic factors for human osteoblasts. *Cytokine* 1995; 7(1): 78-82.